Bladder Outlet Obstruction Clinical Trial
Official title:
Prevalence of Detrusor Underactivity and Bladder Outlet Obstruction in Women With and Without Symptoms of Voiding Dysfunction
Women with symptoms of voiding dysfunction may be associated with detrusor underactivity or bladder outlet obstruction. However, the prevalence of detrusor underactivity and bladder outlet obstruction remained obscure. Thus, the aim of this study was to elucidate the prevalence of detrusor underactivity and bladder outlet obstruction in women with and without symptoms of voiding dysfunction.
Between February 2005 and December 2020, all women with lower urinary tract symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed. Those women who have no complete data of maximum flow rate, voided volume, post-void residual volume and detrusor pressure at maximum flow rate were excluded from this study. Detrusor underactivity was defined when the detrusor pressure at maximum flow rate was less than 20 cmH2O, the maximum flow rate was less than 15 mL/s, and the bladder voiding efficiency was less than 90 %. Bladder outlet obstruction was defined when the the detrusor pressure at maximum flow rate was not less than 40 cmH2O, and the maximum flow rate was less than 12 mL/s. Those women without detrusor interactivity or bladder outlet obstruction were allocated to the non-DU/BOO group. STATA software was used for statistical analysis. Chi2 test, univariate and multivariable logistic regression test were used for statistical analysis as appropriate. A p < 0.05 was considered as statistically significant. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03457805 -
Prostatic Artery Embolization in Advanced Prostate Cancer
|
N/A | |
Completed |
NCT00507455 -
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
|
Phase 2 | |
Recruiting |
NCT04626167 -
Concomitant Renal and Urinary Bladder Allograft Transplantation
|
Early Phase 1 | |
Not yet recruiting |
NCT06422312 -
A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
|
N/A | |
Suspended |
NCT01779349 -
Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter"
|
N/A | |
Not yet recruiting |
NCT01388348 -
Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study
|
N/A | |
Completed |
NCT00710749 -
The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects
|
N/A | |
Recruiting |
NCT03486639 -
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
|
||
Enrolling by invitation |
NCT02869061 -
Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05631080 -
Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer
|
Phase 4 | |
Completed |
NCT02031653 -
Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
|
||
Completed |
NCT00605319 -
An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
|
Phase 4 | |
Recruiting |
NCT03503721 -
Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate
|
N/A | |
Not yet recruiting |
NCT05910983 -
Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity
|
N/A | |
Recruiting |
NCT03281798 -
Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction
|
N/A | |
Completed |
NCT05470751 -
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
|
||
Completed |
NCT00410514 -
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
|
Phase 2 | |
Recruiting |
NCT06152666 -
Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
|
||
Not yet recruiting |
NCT04514718 -
Low Energy HoLEP on IPSS
|
N/A | |
Completed |
NCT01661621 -
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
|
Phase 4 |